Newsletter

Stay up to date on all things Crohn's Disease. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Clinical Hypnosis in Pediatric Crohn’s Disease

September 12, 2019

Overview

Certain therapies may improve physical and psychosocial outcomes in patients with Crohn’s Disease. Among these therapies, clinical hypnosis may improve physical and psychosocial outcomes. This clinical trial studies the effectiveness of clinical hypnosis in children and adolescents. They are believed to be excellent candidates for clinical hypnosis because of their imaginations. Hypnosis is effective in minimizing abdominal pain, irritable bowel syndrome, anxiety, chronic pain, and stress from medical procedures in adults. However, no studies have been conducted on its effectiveness for children.

 

Study Information

This interventional study divides participants into two groups at random: the intervention group and the control group. The intervention group participates in an in-person session of clinical hypnosis, followed by listening to recordings at home to replace discomfort, ease anxiety, and increase energy. The control group will not receive the clinical hypnosis and serve as a comparison to the intervention group.

 

Inclusion Criteria

  • All sexes, ages 12 to 18 years old at the time of enrollment
  • Diagnosed with Crohn’s disease for at least 3 months before enrollment
  • Disease activity determined by Improve Care Now Physician’s Global Assessment (ICN PGA) at most recent gastrointestinal (GI) clinic visit
  • Able to speak, read, and write in English to understand the instructions of the hypnosis session, audio recordings, and surveys
  • Can receive text messages or email, daily

 

Exclusion Criteria

  • Adolescents under the age of 12 and over 18 years old
  • Diagnosed with Crohn’s disease less than 3 months before enrollment
  • Severe disease activity
  • Not able to speak, read, and write in English to understand the instructions of the hypnosis session, audio recordings, and surveys
  • Cannot receive text messages or email, daily

 

Locations

You may participate in this study at Vanderbilt University Medical Center in Nashville, Tennessee, United States, 37232. If you have any questions or concerns, feel free to contact Lynn Walker, PhD at lynn.walker@vumc.org.

 

Sponsors/Collaborators

This clinical trial is sponsored by Vanderbilt University Medical Center with Amanda D. Lee, MD as the Principal Investigator.

Clinical Trials

View All Clinical Trials

The Biologic Onset of Crohn’s Disease: A Screening Study in First Degree Relatives

Early, aggressive diagnostic and therapeutic approaches have proven to improve chances of success in treating many…

Early MRI Prediction of Crohns

Researchers at the Children’s Hospital Medical Center, Cincinnati are translating noncontrast, novel Magnetic…

Corticosteroid Dosage for Crohn’s Disease Flare

The Corticosteroid Dosage for Crohn’s Disease Flare clinical trial compares fixed dosing and weight-based…

Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn’s Disease

Since the inflammatory bowel disease of Crohn’s disease has no cure, researchers are always attempting to uncover…

FMT in Pediatric Crohn’s Disease

This study’s goal is determining the safety of multiple factors that indicate remission in Children from Cron’s…

Autologous Stem Cell Transplant for Crohn’s Disease

Although frequently ineffective, immune cell suppression therapy is widely used to treat Crohn’s disease, an…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend